tecemotide
Vaccineexperimental
Tecemotide is a synthetic lipopeptide that is used as antigen in an investigational therapeutic cancer vaccine. The investigational therapeutic cancer vaccine is designed to induce a cellular immune response to cancer cells that express MUC1, a glycoprotein antigen that is widely over-expressed on common cancers such as lung cancer, breast cancer, prostate cancer, and colorectal cancer. The cellular immune response may lead to a rejection of tumor tissue expressing the MUC1 antigen. — Wikipedia
Clinical trial activity
12 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
11
Phase 3
4
Phase 4
0
Earliest trial started Aug 1, 2000 (NCT00157209)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaTecemotide ↗
- ChEMBLCHEMBL3039544 ↗
Also known as
- blp25
- blp25
- l-blp25
- l-blp25
- l-blp25
- tecemotide
- tecemotide
- tecemotide
- tecemotide
- tecemotide
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02049151 | Phase 3 | Mar 1, 2014 | Merck KGaA, Merck Serono |
| NCT01507103 | Phase 2 | Feb 1, 2012 | Merck KGaA |
| NCT01423760 | N/A | Jan 1, 2012 | Merck KGaA |
| NCT01496131 | Phase 2 | Oct 1, 2011 | Merck KGaA, Merck Serono, National Cancer Institute (NCI) |
| NCT01462513 | Phase 2 | Aug 1, 2011 | Johannes Gutenburg University |
| NCT01015443 | Phase 3 | Dec 1, 2009 | Merck KGaA |
| NCT00925548 | Phase 3 | Sep 1, 2009 | Merck Serono |
| NCT00960115 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2008 | Merck KGaA, Merck Serono |
| NCT01094548 | Phase 2 | Jan 1, 2008 | Merck KGaA |
| NCT00409188 | Phase 3 | Jan 1, 2007 | Merck KGaA, Merck Serono |
| NCT00157196 | Phase 2 | Apr 1, 2005 | Merck KGaA |
| NCT00157209 | Phase 2 | Aug 1, 2000 | Merck KGaA |
Showing 12 of 12 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck KGaA | For profit | 10 | 7 | 3 | 2000 |
| Merck Serono | For profit | 5 | 4 | 2 | 2007 |
| Johannes Gutenburg University | Academic/Hospital | 1 | 1 | 1 | 2011 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2011 |
4 organizations
Page 1 / 1